Why is Sandu Pharmaceuticals Ltd falling/rising?

Recent Price Movement and Market Context

Sandu Pharmaceuticals has been on a downward trajectory over the past fortnight, with the stock falling 5.38% in the last week, closely mirroring the Sensex’s decline of 5.52%. Over the past month, the stock’s performance remains weak, down 5.46%, although it has outperformed the Sensex’s sharper 9.76% fall during the same period. Year-to-date, the stock has declined 12.10%, slightly better than the Sensex’s 12.50% drop, but the longer-term trend is more concerning. Over one year, Sandu Pharmaceuticals has plummeted 36.85%, in stark contrast to the Sensex’s modest 1.00% gain. The three-year and five-year returns further highlight the stock’s underperformance, with losses of 42.29% over three years compared to the Sensex’s 28.03% gain, and a marginal 3.13% rise over five years against the Sensex’s robust 46.80% growth.

Intraday Performance and Technical Indicators

On 13-Mar, the stock opened with a gap down of 2.99%, signalling immediate selling pressure from the outset of trading. The intraday low touched ₹32.36, representing a 5.16% decline from the previous close, and the weighted average price indicates that a larger volume of shares traded closer to this lower price point. This suggests that sellers dominated the session, pushing prices down throughout the day. Furthermore, Sandu Pharmaceuticals is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, reinforcing the bearish technical outlook and indicating sustained downward momentum.

Investor Participation and Liquidity

Interestingly, despite the falling price, investor participation has surged. Delivery volume on 12-Mar rose dramatically by 836.98% compared to the five-day average, reaching 13,630 shares. This spike in delivery volume indicates that more investors are holding shares rather than trading intraday, which could reflect a mix of long-term holders absorbing selling pressure or increased interest at lower price levels. The stock’s liquidity remains adequate, with trading volumes sufficient to support sizeable transactions without excessive price impact, although the traded value is modest.

Comparative Sector and Market Performance

Sandu Pharmaceuticals has underperformed its sector by 1.87% on the day, signalling relative weakness compared to its peers. The stock’s consecutive two-day decline has resulted in a cumulative loss of 6.93%, underscoring the persistent negative sentiment. This underperformance against both sector and benchmark indices suggests that company-specific factors or broader concerns about its fundamentals may be weighing on investor confidence.

Conclusion: Reasons Behind the Decline

The decline in Sandu Pharmaceuticals’ share price on 13-Mar is attributable to a combination of factors. The stock’s failure to hold above key moving averages signals technical weakness, while the gap down opening and intraday low near ₹32.36 reflect strong selling pressure. Although investor participation has increased, this has not translated into price support, indicating that sellers currently outweigh buyers. The stock’s underperformance relative to both the Sensex and its sector peers further highlights challenges in regaining investor confidence. Over the longer term, the stock’s substantial losses compared to the broader market suggest structural issues or market sentiment concerns that continue to weigh on its valuation. Investors should monitor these technical and volume indicators closely, alongside broader market trends, to assess potential entry or exit points.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →